亿胜生物科技早盘高开逾4%,截至发稿,股价上涨2.41%,现报4.68港元,成交额789.34万港元。4月2日,亿胜生物科技发布公告,用以治疗湿性AMD中国患者的anti-VEGF眼用注射生物药品(HLX04-O)的三期临床研究(AURA-1)结果已达到主要研究终点。据介绍,HLX04-O是在复宏汉霖自主研发的汉贝泰? (贝伐珠单抗注射液)的基础上,根据眼科用药的需求对汉贝泰? (贝伐珠单抗注射液...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.